Within the framework of International R&D Nuclis call organized by ACCIÓ, Cytes Biotechnologies has been chosen as a success case for having won the grant that will promote its expansion and international growth.
For this reason, Jordi Xapelli, CEO of Cytes Biotechnologies, SL participated in a talk that took place last Friday, July 17th, where he explained the progress of the project in which the company is involved within this framework.
The aim of this talk was to promote the realization of R+D activities carried out in Catalonia and to facilitate international technological cooperation with foreign entities.
El gen AtCDF3 promueve una mayor producción de az...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Palobiofarma S.L. se complace en anunciar la finalización del tratami...
